New Molecular Insights of Insulin in Diabetic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a highly prevalent disease worldwide. Cardiovascular disorders generated as a consequence of T2DM are a major cause of death related to this disease. Diabetic cardiomyopathy (DCM) is characterized by the morphological, functional and metabolic changes in the heart produced as a complication of T2DM. This cardiac disorder is characterized by constant high blood glucose and lipids levels which eventually generate oxidative stress, defective calcium handling, altered mitochondrial function, inflammation and fibrosis. In this context, insulin is of paramount importance for cardiac contractility, growth and metabolism and therefore, an impaired insulin signaling plays a critical role in the DCM development. However, the exact pathophysiological mechanisms leading to DCM are still a matter of study. Despite the numerous questions raised in the study of DCM, there have also been important findings, such as the role of micro-RNAs (miRNAs), which can not only have the potential of being important biomarkers, but also therapeutic targets. Furthermore, exosomes also arise as an interesting variable to consider, since they represent an important inter-cellular communication mechanism and therefore, they may explain many aspects of the pathophysiology of DCM and their study may lead to the development of therapeutic agents capable of improving insulin signaling. In addition, adenosine and adenosine receptors (ARs) may also play an important role in DCM. Moreover, the possible cross-talk between insulin and ARs may provide new strategies to reverse its defective signaling in the diabetic heart. This review focuses on DCM, the role of insulin in this pathology and the discussion of new molecular insights which may help to understand its underlying mechanisms and generate possible new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bushati, N., & Cohen, S. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123406 · Cited by 2,750
MicroRNA profiling: approaches and considerations
Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3198 · Cited by 1,765
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000442015.53336.12 · Cited by 1,408 · cited 2×
“As we mentioned before, early-stage DCM is characterized by cardiomyocyte hypertrophy and myocardial fibrosis (Battiprolu et al., 2013; Go et al., 2014).”
BackgroundMolecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Regulation of glucose transport by insulin: traffic control of GLUT4
Leto, D., & Saltiel, A. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3351 · Cited by 848
Myocardial Cell Death in Human Diabetes
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1123 · Cited by 796 · cited 1×
“Thus, increased cardiomyocyte apoptosis may be a critical step in the transition from compensated to decompensated HF (Frustaci et al., 2000).”
BackgroundImmunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., Gross, R. W., & Kelly, D. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336724100 · Cited by 501
Mazumder, P. K., O’Neill, B. T., Roberts, M. W., Buchanan, J., Yun, U. J., Cooksey, R. C., Boudina, S., & Abel, E. D. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2366 · Cited by 437
Belke, D. D., Betuing, S., Tuttle, M. J., Graveleau, C., Young, M. E., Pham, M., Zhang, D., Cooksey, R. C., McClain, D. A., Litwin, S. E., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213946 · Cited by 330
Boudina, S., Bugger, H., Sena, S., O'Neill, B. T., Zaha, V. G., Ilkun, O., Wright, J. J., Mazumder, P. K., Palfreyman, E., Tidwell, T. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.792101 · Cited by 301 · cited 16×
“Further extending the evidence for the role of miRNA in the pathophysiology DCM, miR-451 levels were found to be markedly increased in palmitate-stimulated NRCs and DIO mouse heart (model of pre-T2DM and obesity with elevated blood glucose and impaired glucose tolerance).”
BackgroundInfluentialLuiken, J. J. F. P., Koonen, D. P. Y., Willems, J., Zorzano, A., Becker, C., Fischer, Y., Tandon, N. N., van der Vusse, G. J., Bonen, A., & Glatz, J. F. C. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3113 · Cited by 260
Bugger, H., Boudina, S., Hu, X. X., Tuinei, J., Zaha, V. G., Theobald, H. A., Yun, U. J., McQueen, A. P., Wayment, B., Litwin, S. E., et al. (2008) · Diabetes · doi:10.2337/db08-0079 · Cited by 182 · cited 1×
“In contrast, the type 1 diabetic Akita mouse model (Akita) is characterized by normal cardiac function and preservedmyocardial insulin sensitivity, and does not exhibit FAinduced mitochondrial uncoupling (Bugger et al., 2008).”
BackgroundSon, N.-H., Yu, S., Tuinei, J., Arai, K., Hamai, H., Homma, S., Shulman, G. I., Abel, E. D., & Goldberg, I. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40905 · Cited by 159 · cited 1×
“Overexpression of PPARγ led to cardiac lipid accumulation and cardiomyopathy associated with increased FAT/CD36 mRNA, but this effect was antagonized by WY-14,643, a potent PPARα agonist (Son et al., 2010).”
BackgroundInsulin receptor substrate signaling suppresses neonatal autophagy in the heart
Riehle, C., Wende, A. R., Sena, S., Pires, K. M., Pereira, R. O., Zhu, Y., Bugger, H., Frank, D., Bevins, J., Chen, D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71171 · Cited by 114 · cited 2×
“…also participates in myocardial contractility (Fu et al., 2014), protection against ischemia-induced necrotic death (Diaz et al., 2015), autophagy (Riehle et al., 2013), and cell survival, either directly or through the closely associated insulin-like growth factor-1 (IGF-1) (Troncoso et al.,…”
BackgroundRiehle, C., Wende, A. R., Zhu, Y., Oliveira, K. J., Pereira, R. O., Jaishy, B. P., Bevins, J., Valdez, S., Noh, J., Kim, B. J., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00426-14 · Cited by 105
Insulin: An endogenous cardioprotector
Das, U. N. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00007 · Cited by 97
Diabetic cardiomyopathy and metabolic remodeling of the heart
Battiprolu, P. K., Lopez-Crisosto, C., Wang, Z. V., Nemchenko, A., Lavandero, S., & Hill, J. A. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.10.011 · Cited by 91 · cited 3×
“As we mentioned before, early-stage DCM is characterized by cardiomyocyte hypertrophy and myocardial fibrosis (Battiprolu et al., 2013; Go et al., 2014).”
BackgroundSelf-citationMcQueen, A. P., Zhang, D., Hu, P., Swenson, L., Yang, Y., Zaha, V. G., Hoffman, J. L., Yun, U. J., Chakrabarti, G., & Wang, Z. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.07.017 · Cited by 61
Cited by
Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,807
Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease
Jia, G., Whaley-Connell, A., & Sowers, J. R. (2018) · Diabetologia · doi:10.1007/s00125-017-4390-4 · Cited by 868
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., Oliveira, G. M. M. D., Simão, A. F., Dutra, O. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R. M. D. S., Giuliano, I. D. C. B., Alencar Filho, A. C. D., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 434
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
“Some literature suggests an involvement of exosomes in DM-CMP, the extracellular vesicles containing a variety of biological components, including miRNAs, proteins and lipids, which mediate the intercellular communication (220).”
BackgroundCellular senescence links aging and diabetes in cardiovascular disease
Shakeri, H., Lemmens, K., Gevaert, A. B., De Meyer, G. R. Y., & Segers, V. F. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00287.2018 · Cited by 134
“chondrial dysfunction, is also an important underlying cause of diabetic cardiomyopathy (93, 192).”
Background
Metadata
- Authors
- Westermeier, F., Riquelme, J. A., Pavez, M., Garrido, V., Díaz, A., Verdejo, H. E., Castro, P. F., García, L., & Lavandero, S.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2016-04-12
- Volume
- 7
- Pages
- 125-125
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W2315176041
- Cited by
- 111
- References
- 19
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.